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ross.dobie@roslin.ed.ac.ukAbstractThe suppressor of cytokine signalling (Socs2K/K)-knockout mouse is characterised by an
overgrowth phenotype due to enhanced GH signalling. The objective of this study was to
define the Socs2K/K bone phenotype and determine whether GH promotes bone mass via
IGF1-dependent mechanisms. Despite no elevation in systemic IGF1 levels, increased body
weight in 4-week-old Socs2K/K mice following GH treatment was associated with increased
cortical bone area (Ct.Ar) (P!0.01). Furthermore, detailed bone analysis of male and female
juvenile and adult Socs2K/K mice revealed an altered cortical and trabecular phenotype
consistent with the known anabolic effects of GH. Indeed, male Socs2K/Kmice had increased
Ct.Ar (P!0.05) and thickness associated with increased strength. Despite this, there was
no elevation in hepatic Igf1 expression, suggesting that the anabolic bone phenotype was
the result of increased local GH action. Mechanistic studies showed that in osteoblasts and
bone of Socs2K/Kmice, STAT5 phosphorylation was significantly increased in response to GH.
Conversely, overexpression of SOCS2 decreased GH-induced STAT5 signalling. Although an
increase in Igf1 expression was observed in Socs2K/K osteoblasts following GH, it was not
evident in vivo. Igf1 expression levels were not elevated in response to GH in 4-week-old
mice and no alterations in expression was observed in bone samples of 6-week-old Socs2K/K
mice. These studies emphasise the critical role of SOCS2 in controlling the local GH anabolic
bone effects. We provide compelling evidence implicating SOCS2 in the regulation of
GH osteoblast signalling and ultimately bone accrual, which maybe via mechanisms that
are independent of IGF1 production in vivo.Key Words
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.0 UJournal of Endocrinology
(2014) 223, 93–106IntroductionGrowth hormone (GH) is a key regulator of postnatal
skeletal development; however, its mode of action
remains unclear (Slootweg 1993, Ohlsson et al. 1998).
It is likely to involve both endocrine (systemic) actions
via hepatic insulin-like growth factor 1 (IGF1) production
and autocrine/paracrine (local) actions via the osteoblastGH-receptor (GHR). In addition, local GH actions may be
indirect (IGF1 dependent) or direct (IGF1 independent)
(Isgaard et al. 1986, 1989, Le Roith et al. 2001).
The intimate relationship between GH and IGF1
makes it difficult to deduce the relative contributions
of systemic and locally derived IGF1 to bone accrual.sed under a Creative Commons
nported License.
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223 :1 94While GhrK/K mice have recognised changes in skeletal
mass and architecture, these effects may be mediated
through IGF1, as GhrK/Kmice have reduced systemic IGF1
levels (Sims et al. 2000, Sjogren et al. 2000). Global Igf1K/K
and osteoblast-specific Igf1rK/K mice also have altered
bone architecture and diminished osteoid mineralisation
(Bikle et al. 2001, Zhang et al. 2002).
Alterations in systemic IGF1, through the use of
transgenic mouse models, offer an insight into the
endocrine actions of IGF1 on bone turnover. Decreased
systemic IGF1 levels results in an alteration in cortical
geometry, with minimal alteration in trabecular bone
(Sjogren et al. 2002, Yakar et al. 2002). Overexpression of
Igf1 in hepatocytes results in supraphysiological IGF1
levels which is anabolic to cortical bone, and is able to
substitute for skeletally derived IGF1 in global Igf1K/K
mice (Elis et al. 2010). Interpretation of some of these
observations is complex as there is a 4.5-fold increase
in systemic GH levels in LID mice (Yakar et al. 2002).
This may contribute to the bone phenotype, and mask
the effects of low circulating IGF1 levels on bone mass in
this and other mouse models (Yakar et al. 2009). Ideally,
the in vivo study of the local effects of GH on cortical and
trabecular bone formation would benefit from animal
models, in which both circulating GH and IGF1 levels are
normal. Studies with the GHR antagonist pegvisomant
show that in a state of hepatic IGF1 insufficiency, GH
protects the skeleton (Courtland et al. 2011). The targeted
overexpression of Igf1 to osteoblasts indicates that locally
derived IGF1 is anabolic for bone (Zhao et al. 2000).
Conversely, mice with a targeted ablation of Igf1 in
osteoblasts have a catabolic bone phenotype with
no reports of decreased circulating IGF1 levels (Govoni
et al. 2007).
The suppressor of cytokine signalling (SOCS) protein
family consists of at least eight proteins, with SOCS1–3
recognised as inhibitors of GH/IGF1 signal. Basal levels
of these proteins are low, but when stimulated by GH,
expression levels rise quickly (SOCS1 and 3) or more
gradually (SOCS2), forming a negative feedback loop
(Tollet-Egnell et al. 1999). The absence of SOCS2 in mice
results in an overgrowth phenotype (Metcalf et al. 2000).
Firm evidence exists to show that SOCS2 acts on the GH
pathway. The overgrowth phenotype is lost in Socs2K/K;
Ghrhrlit/lit, and diminished in Socs2K/K; Stat5bK/K double-
knockout mice (Greenhalgh et al. 2005, Flores-Morales
et al. 2006). The Socs2K/K mouse is characterised by its
overgrowth skeletal phenotype despite normal serum GH
and IGF1 levels (Metcalf et al. 2000, Greenhalgh et al.
2002, MacRae et al. 2009). Aside from GH, SOCS2 has alsohttp://joe.endocrinology-journals.org
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Printed in Great Britainbeen shown to be upregulated by oestrogen, and it is
possible that GH controls bone mass, architecture, and
strength in a gender-specific manner due to the influence
of oestrogen on SOCS2 expression (Leung et al. 2003).
These data confirm the importance of the direct
anabolic effects of GH, and establish Socs2K/K mice as
an informative model for studying the local effects of GH
on osteoblast function and bone accretion. Whether GH
promotes osteoblast functions via IGF1-dependent and/or
independent mechanisms remains unresolved. This study
therefore explored the mechanisms by which bone
accretion is enhanced in male and female Socs2K/K mice;
and in doing so investigate the mechanisms of local GH
control on osteoblast function.Material and methods
Mice
The Socs2K/K mice used in this study were generated as
described previously (MacRae et al. 2009). For genotyping,
tail or ear biopsied DNA was analysed by PCR for SOCS2
WT or the neocassette (Socs2K/K) using primers (Eurofins
MWG Operon, London, UK) (Supplementary Table 1, see
section on supplementary data given at the end of this
article). All animal experiments were approved by Roslin
Institute’s Animal Users Committee, and the animals
were maintained in accordance with Home Office (UK)
guidelines for the care and use of laboratory animals.GH treatment
From 14 days of age, male WT and Socs2K/Kmice received
a s.c. injection of recombinant human (rh) GH (3 mg/kg),
twice daily for 14 days. The control animals received sterile
water. The mice were weighed each day before the first GH
injection. Three hours after final GH-injection, the mice
were killed. Blood was immediately extracted by cardiac
puncture. The left femurs and livers were dissected, and
the femurs had their epiphysis and marrow removed.
Both livers and femurs were snap frozen in liquid nitrogen
and stored at K80 8C for RNA extraction. Right femurs
were dissected and stored in water at K20 8C for micro-
computed tomography (mCT) analysis.
In addition, male WT and Socs2K/K mice at 24 days
of age were given a single i.p. injection of rhGH (3 mg/kg)
or sterile water for 15 min, before being killed, and livers
and tibiae extracted. The epiphysis was dissected from
the tibiae, and marrow removed by centrifugation.Published by Bioscientifica Ltd
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223 :1 95The samples were snap frozen and stored at K80 8C for
protein extraction.Calcein labelling and tissue collection of adult and
juvenile mice
Male WT and Socs2K/K mice received s.c. injections of
10 mg/kg calcein (Sigma) in sodium bicarbonate solution.
In juvenile mice (6 weeks of age), injections were given 9 and
2 days before being killed. In adult mice (17 weeks of age),
injections were given 16 and 2 days before being killed.
At the point of sacrifice, 6-week-old male and female WT
and Socs2K/Kmice had their liver and right femur dissected
and treated as previously described for RNA analysis. Left
tibiae were also dissected and stored as previously described
for mCT. Right tibiae were dissected for tissue processing.IGF1 and IGFBP3 ELISA
Serum samples were prepared, and total IGF1 levels
were assessed by ELISA according to the manufacturer’s
instructions (Quantikine, R&D Systems, Minneapolis,
MN, USA). IGF1 assays included a step to dissociate the
potentially interfering binding proteins from the ligand.
IGF1 and IGFBP3 levels were also assessed in conditioned
medium of osteoblast cultures (see below).Microcomputed tomography
Tibiae were scanned using a mCT system (Skyscan 1172
X-Ray microtomograph, Bruker Corporation, Kontich,
Belgium) to evaluate trabecular architecture and cortical
bone geometry. For trabecular scanning, high-resolution
scans with an isotropic voxel size of 5 mm were acquired
(60 kV, 0.5 mm aluminium filter, 0.68 rotation angle). The
isotropic voxel size was changed to 10 mm for cortical
analysis. Two images were averaged at each rotation angle.
The scans were reconstructed using NRecon software
(Bruker). For analysis, a 1 mm section of the metaphysis
was taken for the analysis of trabecular bone, using the base
of the growth plate as a standard reference point. A 500 mm
section of the mid-shaft was taken for the analysis of
cortical bone, using the articulation with the fibula as a
standard reference point. CTAn software (Bruker) was used
to analyse the appropriate parameters previously outlined
(Bouxsein et al. 2010).Mechanical testing
A Lloyd LRX5 materials testing machine (Lloyd Instru-
ments, West Sussex, UK) fitted with a 500N load cell washttp://joe.endocrinology-journals.org
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Printed in Great Britainused to determine bone stiffness and the point of failure
of tibiae. The span was fixed at 10 mm, and the cross-head
was lowered at 1 mm/min. Data were recorded after every
0.2 mm change in deflection. Each bone was tested to
failure, with failure points being identified as the point
of maximum load from the load–extension curve. The
maximum stiffness was defined as the maximum gradient
of the rising portion of this curve. Both values were
calculated from a polynomial curve fitted to the rising
region of the load–extension curve in SigmaPlot (Huesa
et al. 2011).Tissue processing and calcein labelling of tibia
Tibiae fixed overnight in 4% paraformaldehyde (PFA) were
embedded in methyl methacrylate. The sections (5 mm) of
the proximal tibia were cut and processed using standard
procedures (Idris et al. 2009). The mineral apposition
rate (MAR) was estimated at both the endosteal and
periosteal surfaces at the mid-diaphysis of each tibia
(Huesa et al. 2011).Osteoblast isolation and culture
Osteoblasts were isolated from the calvaria of 3 to 5-day-
old WT and Socs2K/K mice (Zhu et al. 2011, Prideaux et al.
2012). The cells were pooled, centrifuged, and plated in
aMEM containing 10% foetal bovine serum,and 0.5%
gentamicin (both Invitrogen). The cells were expanded in
flasks in a humidified atmosphere of 95% air/5% CO2, and
maintained at 37 8C until 80–90% confluence. They were
then plated at 10 000 cells/cm2 in multi-well plates.
At confluence, the cells were incubated for 24 h in
serum-free medium containing 0.1% BSA (Sigma). In
keeping with previous studies, the cells were exposed to
500 ng/ml rhGH or 50 ng/ml rhIGF1 (both Bachem,
Merseyside, UK) (DiGirolamo et al. 2007, Pass et al.
2012). Further modifications of this culture protocol are
indicated in the results.RNA extraction and quantitative RT-PCR
RNA was extracted from liver and cultured osteoblast
samples (from above) using an RNeasy Mini Kit (Qiagen
Ltd). Bone samples were homogenised using a mortar and
pestle, and RNA was extracted using TRIzol reagent
(Invitrogen). RNA content was measured by absorbance
at 260 nm, and quality by 260/280 ratios. RT was carried
out as described previously (Farquharson et al. 1999).
RT-qPCR was undertaken using a Stratagene Mx3000PPublished by Bioscientifica Ltd
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223 :1 96real-time qPCR machine with MxPro software (Stratagene,
Santa Clara, CA, USA). Each cDNA sample was normalised
to housekeeping genes Gapdh or Atp5b (Primer Design,
Southampton, UK). The reactions were carried out
with the genes of interest, primers for Igf1 and Igfbp3
(Invitrogen), as well as Socs1, Socs2 and Socs3 (Supple-
mentary Table 1).Protein extraction and western blotting
The cells and tissue were scraped and lysed in either
RIPA buffer or Phospho-Safe lysis buffer (both Sigma),
containing protease inhibitors (Roche). Protein content
was determined using the DC protein assay (Bio-Rad
Laboratories). The lysates were run on 3–8 or 7%
Tris–Acetate gels (for STAT, AKT and ERK1/2 proteins) or
10% Bis–Tris gels (for SOCS protein) (Supplementary
Table 2, see section on supplementary data given at the
end of this article). Following transfer, nitrocellulose
films were blocked in 5% BSA, and probed for 90 min
(STAT, AKT and ERK1/2 proteins) or overnight (SOCS
protein) with primary antibodies. The nitrocellulose was
probed with peroxidase labelled secondary antibodies
for a further 90 min. ECL detection reagents were
used to visualise bands on hyperfilm (Amersham, GE
Healthcare, Bucks, UK). Where necessary, nitrocellulose
was stripped using Restore Plus Stripping Buffer (Perbio
Science, Northumberland, UK). Where appropriate,
densitometry of western blotting was measured on
three independent samples using Image J. Data are
presented as phosphorylated protein normalised to total
protein.Immunofluorescence of cultured cells
Primary osteoblasts isolated from WT and Socs2K/K
mice were grown on collagen-coated glass cover slips.
Following exposure to rhGH (500 ng/ml) for 20 min,
the cells were fixed in 4% PFA (15 min). Following a
PBS wash, they were then permeabilised using methanol
(5 min) at K20 8C. After PBS washing, blocking buffer
(5% normal goat serum/0.3% triton X-100) was added
for 60 min and the cells were probed with pSTAT5
primary antibody overnight and subsequently a
fluorochrome labelled secondary antibody for 60 min
(Supplementary Table 2). Glass cover slips were then
mounted onto slides using ProLong Gold antifade reagent
with DAPI (Invitrogen) and cells were viewed by confocal
microscopy.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great BritainSOCS2 overexpression
The pEF-FLAG-1/mSOCS2 (SOCS2 overexpression;
SOCS2C) and pEF-FLAG-1 (control) plasmids were
obtained from Prof. D Hilton. MC3T3-E1 osteoblast-like
cells (ECACC, Salisbury, UK) were grown to 70% con-
fluency in osteoblast maintenance medium (as mentioned
earlier) and co-transfected with pEF-FLAG-1/mSOCS2 or
pEF-FLAG-1 and PCDNA3.1(C) plasmids at a ratio of 5:1
using FuGene 6 (Roche) as previously described (Pass et al.
2012). Geneticin (Sigma)-resistant colonies were picked
using cloning cylinders (Sigma); expanded, frozen and
maintained atK160 8C.Gene expression profiling
Gene expression profiling for JAK/STAT target genes (84
target genes) was carried out using RT2 profiler PCR arrays
(Qiagen). In accordance with previous studies, osteoblasts
were challenged with rhGH (500 ng/ml) for 4 h to detect
genes directly stimulated by STAT translocation to the
nucleus, and not those downstream of secondary messen-
gers (Greenhalgh et al. 2005, Govoni et al. 2006). RNA was
extracted as described, and 1 mg RNA was reverse tran-
scribed with the RT2 profiler PCR array first-strand
synthesis assay, followed by real-time PCR with RT2 real-
time PCR master mix SYBR green.Statistical analyses
Data were tested for normality and equal variance using
SigmaPlot (v11.0) (Systat Software, Inc., London, UK).
Direct comparison between two sets of data was made
by Student’s t-test. For multiple comparisons, data
were analysed for statistical significance by 2-way
ANOVA incorporating pairwise comparisons. Data are
presented as meanGS.E.M. Values P!0.05 were considered
significant.Results
Increased growth and bone development in
Socs2K/K mice
The increased growth rate of juvenile male Socs2K/K
(103%; P!0.001), as measured by weight gain, was
associated with increased periosteal expansion (Table 1
and Fig. 1A). Detailed analysis revealed increased perios-
teal MAR in the tibiae of male juvenile Socs2K/K mice
(44%; P!0.01), but no change in endosteal MAR (Table 1Published by Bioscientifica Ltd
Table 1 Effects of SOCS2 on bone development in juvenile and adult male mice. Data are presented as meanGS.E.M. nZ3–5 for
growth data and nZ6 for trabecular, cortical and biomechanical data
6 weeks 17 weeks
WT Socs2K/K WT Socs2K/K
Growth
Weight (g) 21.3G0.29 26.1G0.62‡ 32.9G1.68 41.5G1.04‡
Weight gain (g/day) 0.29G0.034 0.59G0.030‡ 0.02G0.030 0.02G0.024
Cortical endosteal MAR (mm/day) 3.3G0.15 3.9G0.07 NA NA
Cortical periosteal MAR (mm/day) 3.6G0.30 5.1G0.25† NA NA
Trabecular
BV/TV (%) 15.4G0.69 20.6G1.72† 14.9G1.9 19.6G1.07*
Tb.N (1/mm) 3.4G0.01 4.0G0.25 3.0G0.41 3.5G0.19
Tb.Th (mm) 0.04G0.001 0.05G0.002† 0.05G0.002 0.06G0.001†
Tb.Sp (mm) 0.17G0.01 0.16G0.01 0.2G0.01 0.18G0.01
SMI 1.9G0.05 1.7G0.08 1.7G0.18 1.5G0.05
BMD (g/cm3) 1.44G0.01 1.46G0.03 1.55G0.006 1.45G0.06
Cortical
Tt.Ar (mm2) 0.8G0.03 1.0G0.03† 0.9G0.06 1.3G0.04‡
Ct.Ar (mm2) 0.6G0.01 0.7G0.03‡ 0.7G0.03 0.9G0.02‡
Ma.Ar (mm2) 0.23G0.016 0.25G0.015 0.25G0.029 0.41G0.018‡
Ct.Th (mm) 0.25G0.008 0.28G0.011† 0.27G0.003 0.28G0.003
J (mm4) 0.10G0.003 0.15G0.012* 0.13G0.016 0.24G0.014‡
BMD (g/cm3) 1.31G0.016 1.29G0.04 1.42G0.002 1.35G0.008*
Biomechanical
Failure load (N) 8.0G0.39 9.4G0.57 11.1G2.46 14.6G1.59*
Work to failure (mJ) 2.6G0.23 3.6G0.34* 3.3G0.71 6.2G2.35*
Load to maximum stiffness (N) 4.4G0.33 4.7G0.41 6.2G1.62 6.8G1.21
Maximum stiffness (N/mm) 18.6G1.52 19.6G3.18 28.4G8.57 30.3G10.57
For trabecular data BV/TV, bone volume/tissue volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structural
model index. For cortical data Tt.Ar, total tissue area; Ct.Ar, cortical bone area; Ma.Ar, medullary area; Ct.Th, cortical thickness; J, polar moment of inertia.
Significance from age-matched WT mice is denoted by *P!0.05, †P!0.01, ‡P!0.001.
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223 :1 97and Fig. 1A). The overgrowth phenotype was still apparent
in adult male Socs2K/K mice (26% heavier; P!0.001);
however, the growth rate was indistinguishable from age-
matched WT mice (Table 1). At this point, double-labelled
calcein was rarely observed in the tibia; suggesting
minimal bone growth.Altered bone architecture and geometry in Socs2K/Kmice
The bone volume/tissue volume of the proximal tibia
was increased in all Socs2K/K mice (juvenile: male 34%
(P!0.01), female 31% (P!0.01); adult: male 32% (P!0.05)
female 24% (P!0.05). This was most likely due to the
increased trabecular thickness noted in the Socs2K/K tibiae
from juvenile (female 15% (P!0.01), male 14% (P!0.01))
and adult mice (female 39% (P!0.001), male 12%
(P!0.01)). The structural model index (SMI) remained
unchanged in the Socs2K/K tibia (Tables 1 and 2). Juvenile
and adult, male and female Socs2K/K mice showed no
alteration in trabecular BMD (Tables 1 and 2).
Analysis of cortical parameters revealed a 27%
(P!0.001) and 28% (P!0.001) increase in cortical bonehttp://joe.endocrinology-journals.org
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Printed in Great Britainarea (Ct.Ar) of the tibiae from juvenile and adult male
Socs2K/K mice respectively. Similar changes were not
noted in the equivalent Socs2K/K female mice (Tables 1
and 2). Grouping both ages together did reveal a genotype
effect (P!0.05). Consistent with increased Ct.Ar, total
tissue area (Tt.Ar) was significantly greater in all Socs2K/K
tibia (P!0.05) (Tables 1 and 2). Increases in marrow space
(Ma.Ar) were, however, far less marked, with only juvenile
female (P!0.001) and adult male (P!0.001) Socs2K/K
tibiae showing increased Ma.Ar. Analysis of male Socs2K/K
tibiae, compared with WT, revealed a significant increase
in cortical thickness (Ct.Th) (P!0.01). Age-defined
analysis revealed that this increase was limited to juvenile
Socs2K/K tibiae (P!0.01). Ct.Th was unchanged in female
Socs2K/K tibiae (Tables 1 and 2). Polar moment of inertia
was increased in the Socs2K/K tibiae of juvenile (female
37% (P!0.05), male 51% (P!0.05)) and adult mice
(female 24% (P!0.05), male 82% (P!0.001)) (Tables 1
and 2). Cortical BMD in juvenile Socs2K/K and WT mice
was similar; however, BMD was significantly decreased
in adult male (P!0.05) and female (P!0.01) Socs2K/K
mice (Tables 1 and 2).Published by Bioscientifica Ltd
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Figure 1
Socs2K/K cortical bone phenotype. (A) Images of periosteal and endosteal
cortical bone apposition rate in tibia from juvenile 6-week-old male WT
and Socs2K/Kmice. Scale barZ25 mm. (B) Load vs extension curves to point
of failure of tibia from juvenile 6-week-old and adult 17-week-old, male
and female WT (black) and Socs2K/K (grey hatched) mice.
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Failure load, work to failure, load to maximum stiffness
and maximum stiffness were unaltered in female Socs2K/K
mice (Fig. 1B and Table 2). In contrast, tibiae from juvenile
male Socs2K/K mice showed a 41% increase in work to
failure (P!0.05). In adult mice, failure load (32%, P!0.05)
and work to failure (90%, P!0.05) were both increased
(Fig. 1B and Table 1). Load to maximum stiffness, and
maximum stiffness of tibiae from male Socs2K/Kmice were
not altered at either age (Table 1).SOCS2 regulates bone growth responses to GH,
independent of elevated systemic IGF1 levels
Comparison of juvenile WT and Socs2K/K mice revealed
that despite the overgrowth phenotype of male (23%;http://joe.endocrinology-journals.org
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Printed in Great BritainP!0.001) and female (18%; P!0.01) Socs2K/K mice
(Tables 1 and 2), transcript levels of hepatic Igf1 were
normal (Fig. 2A). Interestingly, there was a 2.2-fold
increase in Igfbp3 transcript levels in the livers of male
Socs2K/K mice (P!0.05) (Fig. 2A).
To further assess the importance of systemic IGF1
in mediating the actions of GH on bone development in
Socs2K/K mice, male WT and Socs2K/K mice were
administered GH (Fig. 2B). Male Socs2K/K mice treated
with GH showed increased growth following 8 days
treatment (P!0.05) (Fig. 2B). WT mice showed no growth
response at any time-point studied (Fig. 2B). Increased
body weight in Socs2K/K mice was associated with an
anabolic bone phenotype, characterised by increased
Ct.Ar (20%, P!0.01) and polar moment of inertia (43%,
P!0.05) (Table 3). No differences were observed in WT
bone (Table 3). Liver samples extracted at day 24
(representing a stage of GH-induced growth promotion
in Socs2K/K mice) revealed elevated pSTAT5 levels in the
livers of WT (P!0.05) and Socs2K/K (P!0.001) mice
following 15 min GH treatment. The levels of pSTAT5
were much higher in the liver of Socs2K/K mice (Fig. 2C).
Despite increased STAT5 activation, increased growth and
an anabolic bone phenotype (Fig. 2B, C and Table 3),
GH treatment of Socs2K/K mice did not increase hepatic
Igf1 expression or systemic IGF1 levels at day 27 (Fig. 2D
and E). Systemic IGF1 levels in GH-treated Socs2K/K mice
remained similar to those observed for control and
GH-treated WT mice (Fig. 2E). Taken together, these
results emphasise that the overgrowth phenotype noted
in Socs2K/K mice is a result of a non-systemic IGF1-
mediated effects of local GH action.GH upregulates SOCS2 expression by osteoblasts
In WT osteoblasts, GH increased Socs2, but not Socs1 and
Socs3, mRNA expression after 24 h treatment (P!0.001)
(Fig. 3A). This was confirmed and extended by
western blotting analysis following 24 and 48 h GH
treatment (Fig. 3B). IGF1 had no effects on SOCS1,
SOCS2 and SOCS3 transcript or protein expression levels
in WT cells (Fig. 3A and B). These data confirm SOCS2 as
the primary SOCS protein regulating GH signalling in
osteoblasts.SOCS2 negatively regulates GH-STAT intracellular
signalling in osteoblasts and bone
In WT osteoblasts, STAT3 was not activated (pSTAT) in
response to GH, whereas pSTAT1 was only observedPublished by Bioscientifica Ltd
Table 2 Effects of SOCS2 on bone development in juvenile and adult female mice. Data are presented as meanGS.E.M. (nZ6)
6 weeks 17 weeks
WT Socs2K/K WT Socs2K/K
Growth
Weight (g) 16.3G0.62 19.3G0.4† 26.2G0.91 31.3G0.99†
Weight gain (g/day) 0.14G0.04 0.21G0.04 0.06G0.037 0.02G0.05
Trabecular
BV/TV (%) 9.7G0.25 12.7G0.88† 8.0G0.38 9.9G0.52*
Tb.N (1/mm) 2.4G0.09 2.7G0.13* 1.6G0.10 1.4G0.09
Tb.Th (mm) 0.04G0.001 0.05G0.002† 0.05G0.002 0.07G0.001‡
Tb.Sp (mm) 0.22G0.01 0.23G0.01 0.28G0.01 0.33G0.03*
SMI 2.0G0.04 2.0G0.05 2.4G0.28 2.3G0.10
BMD (g/cm3) 1.48G0.006 1.47G0.01 1.56G0.01 1.57G0.01
Cortical
Tt.Ar (mm2) 0.6G0.02 0.7G0.01† 0.7G0.02 0.8G0.04*
Ct.Ar (mm2) 0.4G0.01 0.5G0.01 0.6G0.004 0.6G0.02
Ma.Ar (mm2) 0.19G0.008 0.26G0.008‡ 0.16G0.008 0.12G0.039
Ct.Th (mm) 0.21G0.005 0.20G0.002 0.26G0.009 0.27G0.007
J (mm4) 0.05G0.003 0.07G0.003* 0.08G0.007 0.09G0.007*
BMD (g/cm3) 1.34G0.007 1.32G0.006 1.44G0.005 1.41G0.006†
Biomechanical
Failure load (N) 5.6G0.51 5.7G0.45 9.3G0.54 10.0G0.90
Work to failure (mJ) 2.4G0.31 2.0G0.22 3.0G0.27 3.0G0.26
Load to maximum stiffness (N) 2.7G0.35 2.1G0.27 5.5G0.8 5.7G0.5
Maximum stiffness (N/mm) 11.1G1.32 12.5G0.95 18.2G1.47 22.7G3.42
For trabecular data BV/TV, bone volume/tissue volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structural
model index. For cortical data Tt.Ar, total tissue area; Ct.Ar, cortical bone area; Ma.Ar, medullary area; Ct.Th, cortical thickness; J, polar moment of inertia.
Significance from age-matched WT mice is denoted by *P!0.05, †P!0.01, ‡P!0.001.
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223 :1 99following 15 min of GH exposure. In contrast, pSTAT5 was
observed at all-time points (15–120 min). Phosphorylation
decreased with prolonged GH treatment. In Socs2K/K
osteoblasts, the phosphorylation status of STAT1, STAT3
and STAT5 was both increased and prolonged by GH
compared with WT (Fig. 3C). This was further confirmed
by immunofluorescence where the stimulation of pSTAT5
by GH in both the cytoplasm and nucleus was much
higher in Socs2K/K osteoblasts (Fig. 3D). Increased pSTAT5
levels were also observed in Socs2K/K bone samples
following 15 min GH treatment (P!0.01) (Fig. 3G). The
increase in pSTAT5 levels in bone from WT mice following
GH treatment was far less, and did not reach significance
from control bones (Fig. 3G). Comparable activation of
ERK1/2 was observed in WT and Socs2K/K osteoblasts
following GH treatment, whereas AKT activation was not
observed (Fig. 4A). GH did not stimulate AKT or ERK1/2
activation in bone samples from WT or Socs2K/K mice
following 15 min (Fig. 4C).
IGF1 did not phosphorylate STAT3 or STAT5, and the
phosphorylation of AKT and ERK1/2 in response to IGF1
treatmentwas similar inWTandSocs2K/Kosteoblasts (Fig.4A
and B). These data confirm the negative role of SOCS2 on
GH-induced STAT signalling in osteoblasts and bone.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great BritainOsteoblast SOCS2 overexpression inhibits GH-STAT
intracellular signalling
To fully appreciate the inhibitory role of SOCS2 on
GH-STAT5 signalling, the effects of SOCS2 overexpression
in MC3T3 osteoblast-like cells were investigated (Fig. 3E
and F). In comparison with control osteoblasts, STAT5
phosphorylation in response to GH (15–120 min) was less
in SOCS2 overexpressing cells (Fig. 3E). These results were
confirmed by immunofluorescence (Fig. 3F).Little evidence for local IGF1 regulation of increased
bone mass in Socs2K/K mice
GH caused a small but significant increase in Igf1 (1.32-
fold, P!0.01) and Igfbp3 (1.53-fold, P!0.001) expression
in WT osteoblasts, whereas in Socs2K/K osteoblasts the
increase in both Igf1 (2.39-fold, P!0.001) and Igf1bp3
(2.83-fold, P!0.001) expression was of a slightly greater
magnitude (Fig. 5A). To further identify whether Socs2K/K
osteoblasts had a greater responsiveness to GH, IGF1 and
IGFBP3 protein levels were measured in the conditioned
medium of cultured osteoblasts. In Socs2K/K, the increase
in IGF1 and IGFBP3 protein level following GH treatment,
although significant, was extremely small (1.14-foldPublished by Bioscientifica Ltd
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Figure 2
SOCS2 regulation of systemic IGF1. (A) Transcript analysis of Igf1 and Igfbp3
in liver samples of 6-week-old male and female WT and Socs2K/K mice.
Data represented relative to sex-matched WT as meanGS.E.M. (nZ5).
Significance fromWTsamples denoted by aP!0.05. (B) Graphs showingWT
and Socs2K/K weight gain in response to twice daily GH (3 mg/kg) from
14 to 27 days of age. Data presented as meanGS.E.M. (nR5). Significance
from age-matched WT denoted by aP!0.05, bP!0.01, cP!0.001.
(C) Western blotting analysis of phosphorylated (PK) STAT5 in 24-day-old
WT (KGH (nZ3); CGH (nZ3)) and Socs2K/K (KGH (nZ3); CGH (nZ4))
liver samples following 15 min GH (3 mg/kg) treatment. Band intensities
were quantified by densitometry and analysed for significance, as depicted
in the graphs. Data presented as meanGS.E.M. (nR3). Significance denoted
by aP!0.05, cP!0.001. (D) Transcript analysis of Igf1 in liver samples from
27-day-old WT and Socs2K/K mice following 14 days twice daily GH
(3 mg/kg) treatment. Data presented relative to untreated samples as
meanGS.E.M. (nZ5). (E) Protein analysis by ELISA of IGF1 levels in serum
extracted from 27-day-old WT and Socs2K/K mice following 14 days twice
daily GH (3 mg/kg) treatment.
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223 :1 100(P!0.001) and 1.20-fold (P!0.001) respectively).
No significant changes in IGF1 and IGFBP3 protein levels
were noted in WT osteoblasts (Fig. 5B). No increase in
either Igf1 or Igfbp3 transcript levels was observed in tibia
of WT and Socs2K/K mice administered GH (Fig. 5C).
To directly address the higher bone mass noted in
the Socs2K/K mice, Igf1 and Igf1bp3 mRNA expression
was quantified in femurs from mice previously analysed
by mCT (Tables 1 and 2). The transcript levels ofTable 3 Effects of SOCS2 on cortical bone develo
(3 mg/kg) treatment. Data are presented as meanGS
WT
Control G
Tt.Ar (mm2) 1.33G0.051 1.30G
Ct.Ar (mm2) 0.45G0.023 0.43G
Ma.Ar (mm2) 0.88G0.032 0.87G
Ct.Th (mm) 0.12G0.003 0.12G
J (mm4) 0.17G.0.018 0.15G
For cortical data Tt.Ar, total tissue area; Ct.Ar, cortical bone are
moment of inertia. Significance from genotype-matched cont
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great BritainIgf1 and Igfbp3 in Socs2K/K and WT bones remained
similar (Fig. 5D).Identification of osteoblast genes downstream of the
JAK/STAT pathway stimulated by GH
In WT osteoblasts, the expression profiling revealed a
significant induction of seven genes following 4 h GH
treatment (Sh2b2, Bcl2l1, Fr2, Fcgr1, Gata3, Gbp1 andpment in male mice following 2 weeks rhGH
.E.M. (nR4)
Socs2K/K
H Control GH
0.070 1.27G0.050 1.45G0.070
0.023 0.41G0.009 0.49G0.017†
0.048 0.86G0.050 0.96G0.061
0.003 0.12G0.004 0.13G0.004
0.017 0.14G0.007 0.20G0.015*
a; Ma.Ar, medullary area; Ct.Th, cortical thickness; J, polar
rol group is denoted by *P!0.05, †P!0.01.
Published by Bioscientifica Ltd
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Figure 3
SOCS2 regulation of GH-induced STAT signalling in osteoblasts and bone.
(A) Transcript analysis of Socs1, Socs2 and Socs3 in WTosteoblasts following
24 h GH (500 ng/ml) or IGF1 (50 ng/ml) challenge. Transcript data
represented relative to untreated samples as meansGS.E.M. Significance
denoted by cP!0.001. (B) Western blotting analysis of SOCS1, SOCS2 and
SOCS3 in WT osteoblasts following 24 and 48 h GH (500 ng/ml) or IGF1
(50 ng/ml) treatment. (C) Western blotting analysis of phosphorylated (PK)
STAT1, STAT3, and STAT5 in WT and Socs2K/K osteoblasts challenged with
GH (500 ng/ml) for up to 120 min. (D) Immunofluorescence detection of
pSTAT5 in WT and Socs2K/K osteoblasts following 20 min GH (500 ng/ml)
challenge. (E) Analysis of (PK), STAT5 in SOCS2 overexpressing MC3T3
osteoblast-like cells and negative control-transfected cells following
challenge with GH (500 ng/ml) for up to 120 min. (F) Immunofluorescence
detection of pSTAT5 in SOCS2 overexpressing MC3T3 cells following 20 min
GH (500 ng/ml) challenge. Scale bars for immunofluorescence represent
50 mm. Nucleus, blue; pSTAT5, pink. (G) Analysis of (PK) STAT5 in bone
samples extracted from 24-day-oldWTand Socs2K/Kmice following 15 min
GH (3 mg/kg) treatment. Band intensities were quantified by densitometry
and analysed for significance, as depicted in the graphs. Data presented as
meanGS.E.M. (nZ3). Significance denoted by bP!0.01.
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223 :1 101Socs2). Only two genes showed over a twofold increase
(Fcgr1, 4.46-fold, P!0.05 and Socs2, 4.55-fold, P!0.05)
(Supplementary Figure 1 and Table 3, see section on
supplementary data given at the end of this article).http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great BritainGH-treated Socs2K/K osteoblasts showed a significant
increase in one gene (Cdkn1a) and a significant decrease
in two genes (Sla2 and Stat4), with Stat4 showing a greater
than twofold change (K6.1-fold, P!0.05). In GH-treatedPublished by Bioscientifica Ltd
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Figure 4
SOCS2 regulation of GH or IGF1-induced AKT and ERK1/2 signalling.
(A) Western blotting analysis of phosphorylated (PK) AKTand (PK) ERK1/2
in WT and Socs2K/K osteoblasts challenged with GH (500 ng/ml) or IGF1
(50 ng/ml) for up to 30 min. (B) Analysis of phosphorylated (PK) STAT3 and
STAT5 in WT and Socs2K/K osteoblasts challenged with IGF1 (50 ng/ml) for
up to 30 min. c, GH-treated WT osteoblast acting as a positive control.
(C) Analysisofphosphorylated (PK) AKTandERK1/2 inbone samplesextracted
fromWTand Socs2K/Kmice following 15min GH (3 mg/kg) treatment. Band
intensities were quantified by densitometry and analysed for significance, as
depicted in the graphs. Data presented as meanGS.E.M. (nZ3).
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difference did not reach significance (P!0.076) (Supple-
mentary Figure 1 and Table 3).Discussion
The overgrowth phenotype observed in Socs2K/K mice
exhibits several features of deregulated GH signalling,
including collagen accumulation in the dermis, and the
decreased production of major urinary proteins (Metcalf
et al. 2000, Greenhalgh et al. 2005). Furthermore, Socs2K/K
mice are indistinguishable from WT littermates until 4–6
weeks, which coincides with the period of peak GH activity
that occurs between postnatal days 20 and 40 (Wang et al.
2004). Circulating levels of GH and IGF1 in Socs2K/K mice
are normal; however, it is not known whether this is
a consequence of impaired hepatic GH signalling and
downstream gene transcription. Given that STAT5b is
important for upregulating IGF1 expression, and also
essential for the Socs2K/K overgrowth phenotype, it is
surprising that enhanced GH-induced hepatic STAT5
activation in Socs2K/K mice did not result in raised serum
IGF1 levels (Davey et al. 1999, 2001, Greenhalgh et al. 2002).
Interestingly, several studies have also reported no increase
in basal systemic IGF1 levels in Socs2K/Kmice. This suggestshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great Britainthat the Socs2K/K overgrowth phenotype is a result of
increased endogenous GH signalling at a local level (Metcalf
et al. 2000, Lorentzon et al. 2005, MacRae et al. 2009). In
agreement with this, the present study highlights that the
increased growth observed in juvenile, male and female
Socs2K/K mice was not associated with increased hepatic
Igf1 expression, which is recognised as the main source of
systemic IGF1 (Sjogren et al. 1999, Yakar et al. 1999). Other
GH-regulated genes such as Igfbp3 are preferentially
expressed in the Socs2K/K liver, and this was confirmed in
male, but not in female mice (Rico-Bautista et al. 2005). The
gender-specific effects of GH on Igfbp3 expression have been
noted previously (Bielohuby et al. 2011). These observations
underline the importance of local GH signalling and
confirm the value of the Socs2K/K mouse model in
investigating the direct (IGF1 dependent or independent)
anabolic effects of GH on growth and the skeleton.
In addition to their normal serum GH and IGF1
concentrations, Socs2K/K mice also have normal carbo-
hydrate metabolism (cf Alsko, Bp3ko, Lid and Igf1-null
mice) (Rico-Bautista et al. 2005, Yakar et al. 2009). The
anabolic structural bone changes in Gh-transgenic mice
are similar to those observed in Socs2K/K mice (Eckstein
et al. 2004), but the Gh-transgenic mice suffer from insulin
resistance, which is not observed in the Socs2K/K modelPublished by Bioscientifica Ltd
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Figure 5
SOCS2 regulation of GH-induced IGF1 expression. (A) Transcript analysis
of Igf1, Igfbp3 and Socs2 in WTand Socs2K/K osteoblasts following 48 h GH
(500 ng/ml) treatment. (B) Protein analysis of IGF1 and IGFBP3 from
conditioned medium fromWTand Socs2K/K osteoblasts following 48 h GH
(500 ng/ml) treatment. (C) Transcript analysis of Igf1 and Igfbp3 in bone
samples extracted from 27-day-old male WT and Socs2K/K mice following
14 days twice daily GH (3 mg/kg) treatment. (D) Transcript analysis of Igf1
and Igfbp3 in bone samples extracted from 6-week-old male and female
WT and Socs2K/K mice. All data represented as meansGS.E.M. Significance
from vehicle-treated samples denoted by aP!0.05, cP!0.001.
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223 :1 103(Olsson et al. 2005). Thus, the Socs2K/K mouse may
represent an important model to study the pathways
that promote bone accretion without leading to insulin
resistance and altered carbohydrate metabolism.
The GH/IGF1 pathway is a critical regulator of
osteoblast function, bone homeostasis and ultimately
bone mass (Giustina et al. 2008). Global GH overexpres-
sion results in increased midshaft cross-sectional area;
an observation that is more evident in males (Eckstein
et al. 2004). Conversely, GH deficiency leads to decreased
cortical periosteal circumference, cross-sectional area, and
thickness; however, trabecular bone volume, number and
thickness appear unchanged (Sims et al. 2000, Sjogren et al.
2000). Alterations in systemic IGF1 levels in these models
make it difficult to delineate the relative contributions of
GH and IGF1. Overexpression of GH in osteoblasts results
in increased cortical area and strength, despite no increase
in systemic IGF1 levels (Baker et al. 1992, Tseng et al.
1996). Conversely, overexpression of IGF1 in osteoblasts
reveals an important role for local IGF1 in regulating
trabecular architecture. There were minimal effects on
cortical geometry, suggesting that all GH effects are not
mediated through IGF1 (Zhao et al. 2000).http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great BritainThe present study found many similarities between
the Socs2K/K and GH excess model, including increased
Tt.Ar. This is consistent with previous bone phenotype
analysis of the Socs2K/K mouse model, which focussed
on 7-week-old female mice and the known anabolic
effects of GH (MacRae et al. 2009). The increase in Tt.Ar
is probably a result of increased periosteal bone
formation. Juvenile male Socs2K/K mice had increased
periosteal MAR, which is a commonly used parameter for
the characterisation of bone formation (Schilling et al.
1992). Similar to the GH excess models, male Socs2K/K
mice displayed a more pronounced anabolic phenotype,
with increased Ct.Ar and Ct.Th providing greater support
to the cortex and consequently increasing bone strength
(Davison et al. 2006). The gender-specific differences may
be a consequence of the reported regulatory role of
oestrogen on SOCS2 expression; however, this relation-
ship merits further investigation (Leung et al. 2003). The
increased trabecular bone parameters observed in
juvenile Socs2K/K mice may be secondary to altered
growth plate organisation, which has been previously
reported in similar aged mice (Pass et al. 2012). Increased
trabecular bone is however still evident in adult micePublished by Bioscientifica Ltd
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223 :1 104when growth is negligible and the growth plate has been
reduced to a thin layer of cells. This suggests that in
adult mice, the trabecular bone phenotype is not
secondary to alterations at the growth plate. Previous
studies have produced varying results regarding the
effects of SOCS2 on BMD, with some showing no effect,
while others reporting a decrease (Lorentzon et al. 2005,
MacRae et al. 2009). In this study, we report an age-
dependent decrease in cortical BMD in Socs2K/K mice,
with adults showing a decrease in BMD similar to that
observed in the global GH excess model (Eckstein et al.
2004). Osteoblast-specific GH is anabolic to bone, and
it has been proposed that this is at the expense of
bone tissue integrity, such as increased cortical porosity
which has been used as a predictor of BMD (Tseng et al.
1996, Wachter et al. 2002).
The activation of STAT1, STAT3 and STAT5 has been
implicated in the regulation of gene transcription down-
stream of the GHR in various cell types; however in
osteoblasts, the activation patterns remain unclear (Smit
et al. 1996). In this study, we show that STAT1 and STAT5
are activated in response to GH in WT osteoblasts. In the
absence of SOCS2, the GH-induced phosphorylation of
osteoblast STAT1, STAT3 and STAT5, and the translocation
of pSTAT5 to the osteoblast nucleus are increased
compared with WT cells. The importance of SOCS2 in
the regulation of GH-induced STAT5 activation in bone
was further confirmed in vivo. The reliance of pSTAT5
for SOCS2 regulation of GH signalling has been clearly
demonstrated in Socs2K/K; Stat5bK/K double-knockout
mice whose overgrowth phenotype is minimised
(Greenhalgh et al. 2002). These data suggest that STAT 5
mediates GH anabolic actions on bone as reported for
growth plate chondrocytes and linear bone growth
(Teglund et al. 1998, Pass et al. 2012). Nevertheless, the
bone phenotype of GhrK/K mice is more severe than that
of Stat5abK/K mice, suggesting additional GH actions on
osteoblasts that are STAT5 independent (Sims et al. 2000).
While GH-induced phosphorylation of ERK1/2 in osteo-
blasts, this was not observed in vivo. Likewise, no evidence
for a SOCS2 regulatory role of this pathway was found,
proposing that the high Socs2K/K bone mass was not a
result of increased GH-initiated ERK1/2 pathway.
Although the precise mechanism(s) by which SOCS2
negatively regulates GH signalling is unclear, the
increased GH-induced phosphorylation of STAT1,
STAT3 and STAT5 reported in osteoblasts implies that
the inhibitory actions of SOCS2 are not STAT5 specific
(Pass et al. 2009, Ahmed & Farquharson 2010). The
observation that inhibition or deletion of SOCS2 doeshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0292
 2014 The authors
Printed in Great Britainnot modify GH-induced activation of the ERK1/2 and
AKT pathways advocates that SOCS2 regulates STAT
activation only. A role for SOCS1 and SOCS3 in
negatively regulating the osteoblast STAT response to
GH was not supported by our data and confirms our
previous observations in growth plate chondrocytes
(Pass et al. 2012).
The JAK/STAT pathway is required for GH-induced
IGF1 production, and mice deficient in STAT5b show a
decrease in serum IGF1 levels (Herrington et al. 2000, Sims
et al. 2000). Therefore, in Socs2K/K osteoblasts and bone,
the increased STAT phosphorylation in response to GH is
likely to result in higher Igf1 expression and thereby offer
an explanation for the increased bone mass of Socs2K/K
mice. Previous studies on cultured osteoblasts have
reported that GH has either no effect or causes only a
slight increase in Igf1 expression (Schmid et al. 1994,
DiGirolamo et al. 2007). This study reports similar small
effects on Igf1 and Igfbp3 expression by GH, which were
only slightly enhanced in Socs2K/K osteoblasts. This
indicates that SOCS2 can limit GH’s ability to stimulate
osteoblast Igf1 gene expression. Interestingly, it was also
noted that basal levels of IGF1 and IGFBP3 were elevated
in the condition medium of Socs2K/K osteoblasts. It is
however unlikely that these effects are mediated via GH as
osteoblasts were serum starved. Nevertheless, this obser-
vation warrants further investigation. Our in vitro data,
obtained in a primary cell culture scenario, were however
not confirmed in two separate in vivo models. GH
administration to Socs2K/K mice was anabolic to bone,
but showed no increase in bone Igf1 and Igfbp3 expression.
Similarly, Socs2K/K mice with an over growth phenotype,
increased bone mass and strength had unchanged levels of
bone Igf1 and Igfbp3. The attempts to identify alternative
signalling pathways, downstream of STAT signalling that
are both stimulated by GH and negatively controlled by
SOCS2, were unrewarding. Further studies are required
to identify the specific signalling pathways initiated by
GH’s direct effects on osteoblasts.
In conclusion, this study underscores the critical role
of SOCS2 in controlling GH’s anabolic effects on bone. It
also provides compelling evidence to support the notion
that GH can regulate osteoblast function and ultimately
bone mass via local mechanisms, that in vivo are perhaps
independent of IGF1 production.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
JOE-14-0292.Published by Bioscientifica Ltd
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